Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism

• Management of platinum refractory ovarian cancer is challenging. • Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy. • Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.

Detalles Bibliográficos
Autores principales: Lam, Clarissa, Ha, Kristal, Hakam, Ardeshir, Shahzad, Mian M.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079239/
https://www.ncbi.nlm.nih.gov/pubmed/35540026
http://dx.doi.org/10.1016/j.gore.2022.100992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079239/
https://www.ncbi.nlm.nih.gov/pubmed/35540026
http://dx.doi.org/10.1016/j.gore.2022.100992

Ejemplares similares